• Shares are currently trading at $268.46, up 3.5%, rebounding sharply from the prior session’s decline.
  • Johnson & Johnson highlighted positive primary results from its MEMBRANE randomized controlled trial for chronic subdural haematoma and announced new IMAAVY data at the European Academy of Neurology 2026 Congress.
  • The company is also investing over $1 billion to expand its vision manufacturing operations in Jacksonville, Florida.